Expression of c-sis and other cellular proto-oncogenes in human sarcoma cell lines and biopsies.
Six biopsies (4 of human fibrosarcomas, 1 of a B-cell lymphoma and 1 of a normal lymph node from a melanoma patient) and 6 cell lines (derived from 5 different human osteosarcomas and from 1 rhabdomyosarcoma), together with control cells, were examined for the expression of c-sis, c-fos and c-myc. The expression of c-sis/PDGF-B-related proteins was also examined in cultured cells (not in biopsies). In situ hybridization studies further showed that the occurrence and level of expression of c-sis mRNA and c-sis/PDGF-B-related proteins were significant in the tumor cells. Expression of c-fos and c-myc mRNA did not correlate with c-sis expression. Southern blot analysis of c-sis, c-fos and c-myc of 20 DNAs of cell lines derived from human sarcoma or biopsies showed an identical pattern for BamH1 and EcoR1 restriction fragments of c-sis (except for 1 fibrosarcoma biopsy), implicating no gene rearrangement as a cause of enhanced proto-oncogene expression. The nucleotide sequence of c-sis is highly homologous to that of the viral v-sis oncogene which is capable of transforming infected cells. We conclude that enhanced expression of c-sis in the sarcomas we have examined is involved in the initiation and/or maintenance of the cell transformed state.
Fahrer
C
C
Max von Pettenkofer Institut, University of Munich, FRG.
Brachmann
R
R
von der Helm
K
K
D001706:Biopsy; D015152:Blotting, Northern; D015139:Blotting, Southern; D002460:Cell Line; D015342:DNA Probes; D004273:DNA, Neoplasm / Q000235:genetics; D004591:Electrophoresis, Polyacrylamide Gel; D015972:Gene Expression Regulation, Neoplastic; D015321:Gene Rearrangement / Q000235:genetics; D006801:Humans; D009693:Nucleic Acid Hybridization; D009857:Oncogenes; D011233:Precipitin Tests; D000090063:Proto-Oncogene Mas; D011519:Proto-Oncogenes; D012509:Sarcoma / Q000235:genetics* / Q000473:pathology
D015342:DNA Probes; D004273:DNA, Neoplasm; C000715470:MAS1 protein, human; D000090063:Proto-Oncogene Mas